Brainstorm Cell Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
Management outlined focus on neurodegenerative disorder treatments, ongoing clinical programs, and capital sufficiency for 2025, while highlighting significant risks and uncertainties tied to forward-looking statements.
-
FDA cleared the pivotal phase III-B ALS trial, with manufacturing expansion planned in Israel and the US. Funding remains a key hurdle, with a $15M grant under review and strategic partnerships pursued. The Exosome Program advances with promising preclinical data.
Fiscal Year 2024
-
2024 saw foundational progress for the Phase 3b ALS trial, with regulatory alignment, cost reductions, and new manufacturing partnerships. Financial constraints persist, but recent fundraising and ongoing grant efforts aim to support trial execution and future growth.
-
Key 2024 milestones include FDA SPA agreement for the phase 3B ALS trial, strengthened manufacturing partnerships, and promising biomarker data for NurOwn. The phase 3B trial remains on track for Q1 2025, with ongoing funding efforts and a focus on regulatory compliance.
-
ALS remains a complex disease with high unmet need, but new trial designs for NurOwn focus on early-stage patients and robust biomarker endpoints. Early data show promising efficacy and biomarker shifts, with regulatory alignment under an FDA SPA. Manufacturing and site selection are progressing for rapid trial initiation.
-
Preparations for the Phase 3b ALS trial are on track, with FDA alignment achieved and trial initiation targeted for late 2024 or early 2025. Cash position improved, expenses decreased, and the company is pursuing non-dilutive funding while addressing Nasdaq compliance risks.
-
Alignment with the FDA has enabled the launch of a phase III-B ALS trial, with a leading CRO and commercial manufacturer secured. Recent $4 million funding supports trial initiation, while additional financing is sought. The trial targets early-stage ALS patients, aiming for robust data to support a future BLA.